← back to search

Luboš Petruželka

Charles University · CZ
Area of research
Oncology · Pulmonary and Respiratory Medicine
Research interest
Research interests include Lung Cancer Treatments and Mutations, Cancer Treatment and Pharmacology, Colorectal Cancer Treatments and Studies, and Breast Cancer Treatment Studies.
h-index
38
citations
13,728
works
387
NIH funding
primary concept
Medicine
email

Recent publications

Perioperative Nivolumab in Resectable Lung Cancer
New England Journal of Medicine 2024cited by 413position: middledoi
Immunophenotyping of peripheral blood in NSCLC patients discriminates responders to immune checkpoint inhibitors.
2024cited by 9position: contributordoi
Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study
The Lancet Oncology 2023cited by 100position: middledoi
<i>In vivo</i> Raman spectroscopy in the diagnostics of colon cancer.
2023cited by 17position: contributordoi
Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer
Journal of Clinical Oncology 2020cited by 224position: middledoi
Safety and efficacy of inactivated varicella zoster virus vaccine in immunocompromised patients with malignancies: a two-arm, randomised, double-blind, phase 3 trial
The Lancet Infectious Diseases 2019cited by 36position: middledoi
International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study
The Lancet 2018cited by 2,032position: middledoi
Migrastatics—Anti-metastatic and Anti-invasion Drugs: Promises and Challenges
Trends in cancer 2017cited by 353position: middledoi
Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years after diagnosis of oestrogen receptor-positive breast cancer: ATLAS, a randomised trial
The Lancet 2012cited by 2,030position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

· 2 papers (2023–2024)Thierry Berghmans · Antwerp University Hospital1 papers (2023–2023)Rajiv Panikkar · Geisinger Neuroscience Institute1 papers (2023–2023)Libor Havel · Charles University1 papers (2023–2023)Ticiana Leal · Emory University1 papers (2023–2023)Miklos Pless · Kantonsspital Winterthur1 papers (2023–2023)Joachim G.J.V. Aerts · Erasmus MC1 papers (2023–2023) · 1 papers (2017–2017)Rodryg Ramlau · Foundation for Polish Science1 papers (2023–2023)Zoran Andrić · University Hospital Medical Center Bezanijska kosa1 papers (2023–2023)Wallace Akerley · University of Utah1 papers (2023–2023)Rupesh Kotecha · Dr. Herbert & Nicole Wertheim Family Foundation1 papers (2023–2023) · 1 papers (2017–2017)Goetz Kloecker · University of Louisville1 papers (2023–2023) · 1 papers (2017–2017)Manuel Cobo · Union Hospital1 papers (2023–2023)Richard Greil · EB House Austria1 papers (2023–2023) · 1 papers (2017–2017) · 1 papers (2017–2017)Jaromı́r Roubec · Vítkovická Nemocnice1 papers (2023–2023)